Japan Cancer Vaccines Market Overview
According to SPER Market Research, the Japan Cancer Vaccines Market is estimated to reach USD 4.68 billion by 2033 with a CAGR 18.04%.
The cancer vaccine market is a part of the healthcare industry that focuses on developing vaccines to prevent or treat cancer. Cancer is a disease in which cells in the body grow uncontrollably and can spread to other parts of the body. Cancer vaccines aim to activate the immune system to target and eliminate cancer cells. These vaccines work by either preventing cancer from developing or by treating an existing cancer by slowing its growth or killing cancer cells. The market includes various stakeholders, such as pharmaceutical and biotechnology companies, government agencies, cancer treatment centres, research institutes, investors, patients, and advocacy groups. The ultimate goal of the cancer vaccine market is to provide safe and effective vaccines that can help prevent and treat cancer, improve patient outcomes, and reduce the burden of cancer on society.
Exploring the Growth Drivers of the Japan Cancer Vaccines Industry
The Japan cancer vaccines industry is expected to grow rapidly in the coming years, driven by several factors. One of the major growth drivers is the increasing prevalence of cancer in the country. As the population ages and lifestyles change, the incidence of cancer is expected to rise, creating a greater demand for cancer vaccines. Another growth driver is the supportive regulatory environment in Japan. The Japanese government has been actively promoting the development of new cancer vaccines, providing financial support and regulatory incentives to companies that are working on these products. This has helped to stimulate innovation and investment in the industry, and has made Japan a hub for cancer vaccine research and development.
What challenges does the Japan Cancer Vaccines Market face?
Despite the opportunities for growth, the Japan cancer vaccines market also faces several challenges. One of the major challenges is the high cost of developing and producing cancer vaccines. The process of developing and testing vaccines can be expensive and time-consuming, which can make it difficult for smaller companies to compete in the market. Another challenge is the regulatory landscape in Japan, which can be complex and difficult to navigate. Companies that are developing cancer vaccines must meet strict regulatory requirements and obtain approvals from government agencies, which can be a lengthy and expensive process.
In what ways has the COVID-19 pandemic affected Japan Cancer Vaccines Market?
The COVID-19 pandemic has had a significant impact on the Japan cancer vaccines industry. One of the immediate effects of the pandemic was a disruption in clinical trials, as many hospitals and research centres were closed or diverted their resources to COVID-19 response efforts. This has led to delays in the development and approval of cancer vaccines in Japan. In addition, the pandemic has also caused a shift in priorities and resources, with many companies and research organizations focusing on COVID-19-related research and development. This has led to a reduction in funding and attention for other areas of healthcare, including cancer vaccines.
-01058352052023.jpg)
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Vaccine Type, By Indication, By Patient Type
|
| Regions covered | Tokyo, Kyoto, Osaka, Yokohama, Kobe, Others
|
| Companies Covered | Aduro BioTech Inc., Astellas Pharma Inc., Bristol-Myers Squibb, CYTLIMIC, Oncolys BioPharma Inc., Takara Bio, Takeda Pharmaceutical, tella Inc.
|
Key Target Audience:
- Pharmaceutical and Biotechnology Companies
- Cancer Treatment Centres and Hospitals
- Patients and Caregivers
- Research Institutes
Japan Cancer Vaccines Market Segmentation:
1. By Vaccine Type:
- Japan Cancer Vaccines Market Value Share and Forecast, By Vaccine Type, 2023-2033
- Prevention Vaccines
- Treatment Vaccines
- Oncolytic Viruses
2. By Indication:
- Japan Cancer Vaccines Market Value Share and Forecast, By Indication, 2023-2033
- Prostate Cancer
- Cervical Cancer
- Others
3. By Patient Type:
- Japan Cancer Vaccines Market Value Share and Forecast, By Patient Type, 2023-2033
- Paediatric
- Adult
4. By Region:
- Tokyo
- Kyoto
- Osaka
- Yokohama
- Kobe
- Others
Key Topics Covered in the Report:
- Japan Cancer Vaccines Market Size (FY’2023-FY’2033)
- Overview of Japan Cancer Vaccines Market
- Segmentation of Japan Cancer Vaccines Market By Vaccines Type (Prevention Vaccines, Treatment Vaccines, Oncolytic Viruses)
- Segmentation of Japan Cancer Vaccines Market By Indication (Prostate Cancer, Cervical Cancer, Other)
- Segmentation of Japan Cancer Vaccines Market By Patient Type (Paediatric, Adult)
- Statistical Snap of Japan Cancer Vaccines Market
- Growth Analysis of Japan Cancer Vaccines Market
- Problems and Challenges in Japan Cancer Vaccines Market
- Competitive Landscape in the Japan Cancer Vaccines Market
- Impact of COVID-19 and Demonetization on Japan Cancer Vaccines Market
- Details on Recent Investment in Japan Cancer Vaccines Market
- Competitive Analysis of Japan Cancer Vaccines Market
- Key Players in the Japan Cancer Vaccines Market
- SWOT Analysis of Japan Cancer Vaccines Market
- Japan Cancer Vaccines Market Future Outlook and Projections (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Japan Cancer Vaccines Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Japan Cancer Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Japan Cancer Vaccines Market
7. Japan Cancer Vaccines Market, By Vaccine Type (USD Million)
7.1. Japan Cancer Vaccines Market Value Share and Forecast, By Vaccine Type, 2023-2033
7.2. Prevention Vaccines
7.2.1. HPV
7.2.2. HBV
7.3. Treatment Vaccines
7.3.1. Antigen vaccines
7.3.2. Dendritic cell vaccines
7.3.3. DNA vaccines
7.3.4. Whole tumor vaccines
7.3.5. Anti-idiotype vaccines
7.4. Oncolytic Viruses
8. Japan Cancer Vaccines Market, By Indication (USD Million)
8.1. Japan Cancer Vaccines Market Value Share and Forecast, By Indication, 2023-2033
8.2. Prostate Cancer
8.3. Cervical Cancer
8.4. Others
9. Japan Cancer Vaccines Market, By Patient Type (USD Million)
9.1. Japan Cancer Vaccines Market Value Share and Forecast, By Patient Type, 2023-2033
9.2. Paediatric
9.3. Adult
10. Japan Cancer Vaccines Market Forecast, 2019-2033 (USD Million)
10.1. Japan Cancer Vaccines Market Size and Market Share
11. Japan Cancer Vaccines Market, By Vaccine Type, 2019-2033 (USD Million)
11.1. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2019-2026)
11.2. Japan Cancer Vaccines Market Size and Market Share by Vaccine Type (2027-2033)
12. Japan Cancer Vaccines Market, By Indication, 2019-2033 (USD Million)
12.1. Japan Cancer Vaccines Market Size and Market Share by Indication (2019-2026)
12.2. Japan Cancer Vaccines Market Size and Market Share by Indication (2027-2033)
13. Japan Cancer Vaccines Market, By Patient Type, 2019-2033 (USD Million)
13.1. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2019-2026)
13.2. Japan Cancer Vaccines Market Size and Market Share by Patient Type (2027-2033)
14. Japan Cancer Vaccines Market, By Region, 2019-2033 (USD Million)
14.1. Japan Cancer Vaccines Market Size and Market Share by Region (2019-2026)
14.2. Japan Cancer Vaccines Market Size and Market Share by Region (2027-2033)
14.3. Tokyo
14.4. Kyoto
14.5. Osaka
14.6. Yokohama
14.7. Kobe
14.8. Others
15. Company Profile
15.1. Aduro BioTech Inc.
15.1.1. Company details
15.1.2. Financial outlook
15.1.3. Product summary
15.1.4. Recent developments
15.2. Astellas Pharma Inc.
15.2.1. Company details
15.2.2. Financial outlook
15.2.3. Product summary
15.2.4. Recent developments
15.3. Bristol-Myers Squibb
15.3.1. Company details
15.3.2. Financial outlook
15.3.3. Product summary
15.3.4. Recent developments
15.4. CYTLIMIC
15.4.1. Company details
15.4.2. Financial outlook
15.4.3. Product summary
15.4.4. Recent developments
15.5. Oncolys BioPharma Inc.
15.5.1. Company details
15.5.2. Financial outlook
15.5.3. Product summary
15.5.4. Recent developments
15.6. Takara Bio
15.6.1. Company details
15.6.2. Financial outlook
15.6.3. Product summary
15.6.4. Recent developments
15.7. Takeda Pharmaceutical
15.7.1. Company details
15.7.2. Financial outlook
15.7.3. Product summary
15.7.4. Recent developments
15.8. tella Inc
15.8.1. Company details
15.8.2. Financial outlook
15.8.3. Product summary
15.8.4. Recent developments
16. List of Abbreviations
17. Reference Links
18. Conclusion
19. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
